April 2014 Blog Posts (16)

Researchers Identify Novel Regulator of Key Gene Expression in Cancer - Leading to New targets for Treatment

Researchers at the Salk Institute for Biological Studies, one of the world's preeminent basic research institutions based in San Diego, Ca, have identified a key genetic switch linked to the development, progression and outcome of cancer. This finding, the researchers conclude, may lead to new targets for cancer therapies.

The switch, a string of nucleotides dubbed a long non-coding RNA or lncRNA,…

Continue

Added by Editorial Team on April 30, 2014 at 8:30am — No Comments

Dana-Farber-led Study of Ramucirumab was Key to FDA's Approval of First Targeted Drug for Advanced Stomach Cancer

Based on results of a clinical trial led by scientists from the Dana-Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

The FDA approval after a priority review was announced by the manufacturer,…

Continue

Added by Editorial Team on April 21, 2014 at 10:00am — No Comments

Macrophages are ‘Big Eaters’ Indeed: Circulating Tumor Cells are Devoured after Monoclonal Antibody Therapy.

Contributing Editor: Marjolein van Egmond, Ph.D; Department of Surgery and the Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands. doi: 10.14229/ONCO.2014.4.16.002

Monoclonal antibodies (mAbs) are a valuable addition to the current arsenal of anti-cancer therapies. We demonstrated that after…

Continue

Added by Editorial Team on April 18, 2014 at 10:30am — No Comments

Study Shows Outpatient Diagnostic Errors Affecting 1 in 20 American Adults

Diagnostic errors are a serious problem and can fatal. However, according to a new study to be published in the April 21, 2014 edition of the journal BMJ Quality & Safety (previously called Quality & Safety in Health Care), these missed opportunities to make a timely or correct diagnosis based on available evidence occur in about 5% of adults in the United States. The study, partially funded by the Agency for…

Continue

Added by Editorial Team on April 16, 2014 at 10:00pm — No Comments

Protein Partnership has Implications for Cancer Treatment

Scientists have identified two unlikely partners in a type of immune cell called a macrophage that work together in response to cancer drugs. These two partners are working together to increase inflammation in a way that may alter tumor growth. Researchers from the National Institutes of Health published the study in the April 15, 2014 edition of the journal Cancer Research.

These two…

Continue

Added by Editorial Team on April 15, 2014 at 9:30pm — No Comments

Genetic Evidence Supports Role of Gene family in Cancer Development

Researchers from the Wellcome Trust Sanger Institute in Hinxton, Cambridgeshire, United Kingdom, have found a major piece of genetic evidence that confirms the role of a group of virus-fighting genes in cancer development. Their study was published in the April 13, 2014 online edition of Nature Genetics.[1]

The general…

Continue

Added by Editorial Team on April 14, 2014 at 9:30pm — No Comments

Drinking More Coffee may Reduce Risk of Liver Cancer

A study funded by the National Cancer Institute (NCI) shows that the more cups of coffee a person drinks, the lower the risk for developing hepatocellular carcinoma (HCC), the most common solid tumor worldwide and the third leading cause of cancer-related deaths. The results of the study were presented at the Annual Meeting of the American Association for Cancer Research (AACR), being held in San Diego, CA, USA, April 5-9, 2014. [1][2]

This study found that compared with…

Continue

Added by Editorial Team on April 9, 2014 at 9:30pm — No Comments

Study Confirms Pre-diagnosis Obesity Predicts Poor Outcome for Colorectal Cancer Patients

A High Body Mass Index or BMI is an indicator of obesity, which has consistently been linked to colorectal cancer, even before a colorectal cancer (CRC) diagnosis was associated with increased risk of death after diagnosis. This increased risk was, according to results of a large prospective study presented at the Annual Meeting of the American Association for Cancer Research (AACR), being held in San Diego, CA, USA, April 5-9, 2014, also observed when tumors harbored the microsatellite…

Continue

Added by Editorial Team on April 9, 2014 at 9:00pm — No Comments

Irregular and Infrequent Menstruation May Predict a Woman's Increased Risk of Death From Ovarian Cancer

A a large, prospective study funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development,institute of the National Institutes of Health, shows that women with irregular menstrual cycles have a twofold increased risk of death from ovarian cancer.  The study was presented at the Annual Meeting of the American Association for Cancer Research (AACR), being held in San Diego, CA,…

Continue

Added by Editorial Team on April 9, 2014 at 11:30am — No Comments

LIVESTRONG Emphasizes Importance of Patient-Focused Cancer Care

By Melissa Stewart, Contributing Editor and Director of Navigation Services, The LIVESTRONG Foundation doi: 10.14229/ONCO.2014.4.16.001

Recently, an INC Magazine interview, asked, “What’s next for the LIVESTRONG Foundation?” I’m always invigorated by that question…

Continue

Added by Editorial Team on April 9, 2014 at 10:30am — No Comments

First Patient Dosed in Tecemotide Phase III START2 Trial

Earlier today, EMD Serono, Inc., a subsidiary of Germann based Merck KGaA, Germany announced the initiation of the international Phase III Stimulating Targeted Antigenic Responses To NSCLC or START2 study, which is designed to assess the efficacy and safety of its investigational MUC1 antigen specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).

The START2 study is a Phase…

Continue

Added by Editorial Team on April 7, 2014 at 12:00am — No Comments

New Cyclin-dependent Kinases Inhibitor Shows Promise in Metastatic Breast Cancer

Phase I study results presented at the Annual Meeting of the American Association for Cancer Research (AACR), being held in San Diego, CA, USA, April 5-9, 2014, demonstrates that a new oral drug called LY2835219, a cyclin-dependent kinases (CDKs) CDK4 and CDK6 inhibitor, shows early promise as monotherapy for patients with metastatic breast cancer, particularly for those with hormone receptor (HR)-positive disease. 

Many tumors, including…

Continue

Added by Editorial Team on April 6, 2014 at 4:30pm — No Comments

Better Outcome Predicted in Patients With Lung Cancer Treated With the Investigational Immunotherapy MK-3475

Among patients with non-small cell lung cancer (NSCLC) treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes.  This was the conclusion of a phase I clinical trial presented at the Annual Meeting of the American Association for Cancer Research (AACR) being held in San Diego, CA, USA, April 5-9, 2014

Preliminary data from…

Continue

Added by Editorial Team on April 6, 2014 at 4:30pm — No Comments

First-line Treatment with Palbociclib in Patients with Hormone Receptor-positive, Metastatic Breast Cancer Shows Improved Progression-free Survival

Palbociclib (formally PD-0332991; Pfizer), an inhibitor of cyclin-dependent kinases (CDKs) CDK4 and CDK6, made its debut in 2012 at the Annual San Antonio Breast Cancer Symposium when researchers from the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, presented interim results from the PALOMA-1 trial. Now new, updated results show that the drug significantly improved progression-free survival when administered as a first-line treatment in patients with…

Continue

Added by Editorial Team on April 6, 2014 at 4:00pm — No Comments

Study Shows Major Difference Between Patients with PD-L1-positive and PD-L1-negative Tumors Treated With MK-3475

A recent study showed that among melanoma patients treated with the PD-1 inhibitor MK-3475, those whose tumors had the protein PD-L1 had better immune responses and higher survival rates.  The results were presented at the Annual Meeting of the American Association for Cancer Research (AACR), being held in San Diego, April 5-9, 2014. 

The researchers found that when the protein PD-L1, which is present on some melanoma tumors, binds to PD-1, a protein present on T cells,…

Continue

Added by Editorial Team on April 6, 2014 at 3:30pm — No Comments

AG-221 Shows Clinical Activity in Advanced Hematological Cancers

According to the initial results of a phase I study presented at the Annual Meeting of the American Association for Cancer Research (AACR),  the world's oldest and largest professional association related to cancer research being held in San Diego, CA, USA, April 5-9, 2014, a novel, first-in-class inhibitor of isocitrate dehydrogenase (IDH) 2-mutant metabolic enzyme called AG-221 was well tolerated and showed early promise in patients with advanced and refractory hematological cancers…

Continue

Added by Editorial Team on April 6, 2014 at 3:30pm — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+